Article

Antipsychotic Drug May Reduce Chemotherapy Side Effects

Olanzapine found to reduce chemotherapy-induced nausea and vomiting in cancer patients.

An FDA approved antipsychotic agent was found to significantly reduce chemotherapy-induced nausea and vomiting in cancer patients.

In a study published in the New England Journal of Medicine, researchers discovered that the drug olanzapine was able to block neurotransmitters involved in nausea and vomiting. Patients were randomized to receive chemotherapy plus olanzapine, or chemotherapy and a placebo.

The results of the study showed that 74% of patients who received olanzapine plus chemotherapy did not experience nausea or vomiting after the first day of treatment. In the placebo group, the number dropped to 45%.

Many of the participants who benefited from the treatment continued to be free of side effects for 5 days after chemotherapy.

“We’ve long known that nausea and vomiting that come along with chemotherapy are a major problem and affect the quality of life of our patients,” said researcher Steven Powell, MD. “The findings of this study, fortunately, provide physicians with a tool to better address the needs of those they are treating for cancer.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards